神經保護市場 - 副產品（抗氧化劑、細胞凋亡抑制劑、抗發炎藥物、谷氨酸拮抗劑、金屬離子螯合劑、抗憂鬱藥物）、給藥途徑、應用、配銷通路- 全球預測 2024 - 2032

由於該領域的研究和開發不斷增加，2024 年至 2032 年全球神經保護市場的複合年成長率將達到 7.1%。神經保護涉及旨在保護大腦和神經系統中神經元的結構和功能的策略。隨著我們對神經系統疾病和損傷的了解不斷加深，對有效神經保護治療的需求也不斷增加。

例如，2023 年 10 月，兩項關於針對急性缺血性中風患者的潛在神經保護劑 nerinetide (NoNO Inc) 的最新研究揭示了相互矛盾但有趣的發現。領導 ESCAPE-NEXT 試驗的加拿大卡加利大學神經病學教授 Michael Hill 博士承認該試驗的結果令人失望。然而，他表示 FRONTIER 結果非常有希望，並表明儘早使用該藥物的重要性。

研究人員正在探索各種方法，包括藥物介入、基因治療、幹細胞治療和神經保護劑。隨著神經科學的進步，人們越來越樂觀地開發新療法來預防或減緩阿茲海默症、帕金森氏症和多發性硬化症等神經退化性疾病的進展。因此，對神經保護療法的需求不斷成長，推動了神經保護市場的成長。

整個神經保護產業根據產品、給藥途徑、應用、配銷通路和地區進行分類。

細胞凋亡抑制劑領域將在 2024 年至 2032 年經歷顯著發展。細胞凋亡抑制劑旨在阻斷此過程，保留神經元功能和結構。這些抑制劑有望治療中風、阿茲海默症和帕金森氏症等疾病。隨著研究的進展，更有效的細胞凋亡抑制劑正在開發中，推動了神經保護市場的需求。細胞凋亡抑制劑可能減緩或阻止神經退化的能力使它們成為尋求新型神經保護療法的焦點。

從 2024 年到 2032 年，靜脈注射領域的神經保護市場佔有率將實現顯著的複合年成長率。這種途徑對於中風、腦部外傷和神經退化性疾病等需要立即採取行動的急性疾病尤其重要。此外，靜脈注射可以實現精確劑量和連續輸注，從而最佳化治療效果。隨著研究人員開發出適合靜脈注射的新型神經保護劑和製劑，對此類治療的需求持續成長，從而塑造了神經保護市場格局。

亞太地區神經保護市場從2024年到2032年將呈現出令人稱讚的複合年成長率。亞太地區國家正在投資醫療基礎設施和研究，促進神經保護療法的創新和發展。此外，可支配收入的增加和對神經健康的認知正在推動對這些治療的需求。各國政府正在實施政策來滿足醫療保健需求，進一步推動市場成長。因此，亞太地區正在成為神經保護研究和開發的焦點，推動對神經保護療法的需求。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 神經系統疾病盛行率增加
    • 藥物輸送系統的技術進步
    • 人口老化與人口結構變化
    • 增加研發投入
  • 產業陷阱與挑戰
    • 嚴格的監管場景
• 成長潛力分析
• 技術景觀
• 監管環境
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 競爭定位矩陣
• 戰略展望矩陣

第 5 章：市場估計與預測：按產品分類，2018 年 - 2032 年

• 主要趨勢
• 抗氧化劑
• 細胞凋亡抑制劑
• 抗發炎劑
• 麩胺酸拮抗劑
• 金屬離子螯合劑
• 抗憂鬱藥
• 興奮劑
• 神經營養因子 (NTF)
• 其他產品

第 6 章：市場估計與預測：按管理途徑，2018 年 - 2032 年

• 主要趨勢
• 口服
• 靜脈
• 其他給藥途徑

第 7 章：市場估計與預測：按應用分類，2018 年 - 2032 年

• 主要趨勢
• 神經退化性疾病
• 中風和缺血性損傷
• 創傷性腦損傷 (TBI)
• 憂鬱症和躁鬱症
• 脊髓損傷
• 其他應用

第 8 章：市場估計與預測：按配銷通路，2018 年 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 藥局
• 網路藥局

第 9 章：市場估計與預測：按地區分類，2018 年 - 2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 10 章：公司簡介

• AbbVie Inc.
• Biogen Inc.
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• GSK plc
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Limited

Global Neuroprotection Market will witness 7.1% CAGR between 2024 and 2032 due to increasing research and development in the field. Neuroprotection involves strategies aimed at preserving the structure and function of neurons in the brain and nervous system. As our understanding of neurological diseases and injuries improves, so does the need for effective neuroprotective treatments.

For instance, in October 2023, two recent studies on the potential neuroprotective agent nerinetide (NoNO Inc) for acute ischemic stroke patients revealed conflicting yet intriguing findings. Michael Hill, MD, a neurology professor at the University of Calgary, Canada, who led the ESCAPE-NEXT trial, admitted that the trial's results were disappointing. However, he expressed that the FRONTIER results were highly promising and indicated the importance of administering this agent as early as feasible.

Researchers are exploring various approaches, including pharmacological interventions, gene therapy, stem cell therapy, and neuroprotective agents. With advancements in neuroscience, there is growing optimism for the development of novel treatments to prevent or slow down the progression of neurodegenerative diseases like Alzheimer's, Parkinson's, and multiple sclerosis. Consequently, there is a rising demand for neuroprotective therapies, driving growth in the neuroprotection market.

The overall Neuroprotection Industry is classified based on the product, route of administration, application, distribution channel, and region.

The apoptosis inhibitors segment will undergo notable development from 2024 to 2032. Apoptosis, or programmed cell death, plays a significant role in neurodegenerative diseases and injuries by causing the death of neurons. Apoptosis inhibitors are designed to block this process, preserving neuronal function and structure. These inhibitors hold promise in treating conditions like stroke, Alzheimer's, and Parkinson's disease. As research advances, more effective apoptosis inhibitors are being developed, driving demand in the neuroprotection market. The ability of apoptosis inhibitors to potentially slow or halt neurodegeneration makes them a focal point in the quest for novel neuroprotective therapies.

The neuroprotection market share from the intravenous segment will register a noteworthy CAGR from 2024 to 2032. Intravenous delivery offers direct and rapid access to the bloodstream, ensuring efficient distribution of neuroprotective agents to the brain and spinal cord. This route is particularly crucial in acute conditions like stroke, traumatic brain injury, and neurodegenerative diseases where immediate action is required. Additionally, intravenous administration allows for precise dosing and continuous infusion, optimizing therapeutic outcomes. As researchers develop new neuroprotective agents and formulations suitable for intravenous delivery, the demand for such treatments continues to grow, shaping the neuroprotection market landscape.

Asia Pacific neuroprotection market will showcase a commendable CAGR from 2024 to 2032. With a rapidly aging population and increasing incidence of neurological disorders, there's a pressing need for effective treatments. Countries in Asia-Pacific are investing in healthcare infrastructure and research, fostering innovation and development of neuroprotective therapies. Moreover, rising disposable incomes and awareness about neurological health are propelling demand for these treatments. Governments are implementing policies to address healthcare needs, further boosting market growth. As a result, the Asia-Pacific region is becoming a focal point for neuroprotection research and development, driving demand for neuroprotective therapies.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of neurological disorders
    • 3.2.1.2 Technological advancements in drug delivery systems
    • 3.2.1.3 Aging population and demographic shifts
    • 3.2.1.4 Increasing research and development investments
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Antioxidants
• 5.3 Apoptosis inhibitors
• 5.4 Anti-inflammatory agents
• 5.5 Glutamate antagonists
• 5.6 Metal ion chelators
• 5.7 Antidepressants
• 5.8 Stimulants
• 5.9 Neurotrophic factors (NTFs)
• 5.10 Other products

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Intravenous
• 6.4 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Neurodegenerative diseases
• 7.3 Stroke and ischemic injury
• 7.4 Traumatic brain injury (TBI)
• 7.5 Depression and bipolar disorders
• 7.6 Spinal cord injury
• 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Drug stores
• 8.5 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Biogen Inc.
• 10.3 Dr. Reddy's Laboratories Ltd.
• 10.4 Eli Lilly and Company
• 10.5 GSK plc
• 10.6 Merck & Co., Inc.
• 10.7 Novartis AG
• 10.8 Pfizer Inc.
• 10.9 Sanofi
• 10.10 Teva Pharmaceutical Industries Limited